PT Bundamedik TbkISX:BMHS -1.65%61 Piotroski F-Score is 6 as of Jun. 30, 2026, which is at its 10-year median of 6.00. GuruFocus rates ISX:BMHS with a GF Score™ of 61/100 and a GF Value™ of Rp304.24 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 650 Healthcare Providers & Services companies, PT Bundamedik Tbk ranks better than 74.62% on this metric.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
PT Bundamedik Tbk has an F-score of 6 indicating the company's financial situation is typical for a stable company.
The historical rank and industry rank for PT Bundamedik Tbk's Piotroski F-Score or its related term are showing as below:
ISX:BMHS'
s Piotroski F-Score Range Over the Past 10 Years
Min: 4 Med: 6 Max: 7
Current: 6
During the past 8 years, the highest Piotroski F-Score of PT Bundamedik Tbk was 7. The lowest was 4. And the median was 6.
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
PT Bundamedik Tbk Piotroski F-Score Related Terms
PT Bundamedik Tbk Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for PT Bundamedik Tbk's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ISX:BMHS vs HCA, THC, DVA: Piotroski F-Score Comparison
For the Medical Care Facilities subindustry, PT Bundamedik Tbk's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Bundamedik Tbk Piotroski F-Score vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, PT Bundamedik Tbk's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where PT Bundamedik Tbk's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This Year (Mar26) TTM:
Last Year (Mar25) TTM:
Net Income was 630.303 + 8346.188 + 170.33 + 65.715 = Rp9,213 Mil. Cash Flow from Operations was 4733.952 + 16030.679 + 199643.171 + 273.623 = Rp220,681 Mil. Revenue was 378770.255 + 397092.444 + 459448.484 + 371093.607 = Rp1,606,405 Mil. Gross Profit was 173734.48 + 193951.547 + 206174.073 + 170616.921 = Rp744,477 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(3491225.789 + 3526414.842 + 3635619.911 + 4016429.435 + 4042907.843) / 5 = Rp3742519.564 Mil. Total Assets at the begining of this year (Mar25) was Rp3,491,226 Mil. Long-Term Debt & Capital Lease Obligation was Rp890,026 Mil. Total Current Assets was Rp1,224,556 Mil. Total Current Liabilities was Rp721,025 Mil.
Net Income was 93.496 + 831.529 + 148.534 + 3272.139 = Rp4,346 Mil.
Revenue was 370730.138 + 372469.662 + 397734.035 + 379029.589 = Rp1,519,963 Mil. Gross Profit was 175143.37 + 175475.205 + 161934.709 + 170632.366 = Rp683,186 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(3139014.921 + 3180765.411 + 3774167.721 + 3446360.904 + 3491225.789) / 5 = Rp3406306.9492 Mil. Total Assets at the begining of last year (Mar24) was Rp3,139,015 Mil. Long-Term Debt & Capital Lease Obligation was Rp725,863 Mil. Total Current Assets was Rp1,082,646 Mil. Total Current Liabilities was Rp582,536 Mil.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
PT Bundamedik Tbk's current Net Income (TTM) was 9,213.
==> Positive ==> Score 1.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
PT Bundamedik Tbk's return on assets of this year was 0.00263877. PT Bundamedik Tbk's return on assets of last year was 0.00138441.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
PT Bundamedik Tbk's gearing of this year was 0.23781462. PT Bundamedik Tbk's gearing of last year was 0.21309397.
==> Last year is lower than this year ==> Score 0.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
PT Bundamedik Tbk's current ratio of this year was 1.69835426. PT Bundamedik Tbk's current ratio of last year was 1.85850539.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
PT Bundamedik Tbk's number of shares in issue this year was 8603.416. PT Bundamedik Tbk's number of shares in issue last year was 8603.416.
==> There is smaller number of shares in issue this year, or the same. ==> Score 1.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
PT Bundamedik Tbk's gross margin of this year was 0.46344298. PT Bundamedik Tbk's gross margin of last year was 0.44947506.
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
PT Bundamedik Tbk's asset turnover of this year was 0.4601263. PT Bundamedik Tbk's asset turnover of last year was 0.48421669.
==> Last year's asset turnover is higher ==> Score 0.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
1
+
1
+
1
+
1
+
0
+
0
+
1
+
1
+
0
=
6
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
PT Bundamedik Tbk has an F-score of 6 indicating the company's financial situation is typical for a stable company.
PT Bundamedik Tbk (ISX:BMHS) has a Piotroski F-Score of 6 as of Jun. 30, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on PT Bundamedik Tbk and its competitors. This is near median its historical median of 6.00. Over the past decade, PT Bundamedik Tbk's Piotroski F-Score has ranged from 4.00 to 7.00. According to the industry distribution chart, PT Bundamedik Tbk ranks #165 out of 650 companies in the Healthcare Providers & Services industry, placing it in the top 25.4%.
Is PT Bundamedik Tbk's Piotroski F-Score too high?
PT Bundamedik Tbk's current Piotroski F-Score of 6 is near median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 7.00. The Healthcare Providers & Services industry median Piotroski F-Score is 5.00. PT Bundamedik Tbk's value of 6 is 20% above this industry median. Based on the distribution chart, PT Bundamedik Tbk ranks #165 out of 650 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, PT Bundamedik Tbk has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does PT Bundamedik Tbk's Piotroski F-Score compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, PT Bundamedik Tbk ranks #165 out of 650 companies for Piotroski F-Score. This puts PT Bundamedik Tbk in the upper half of its industry. The industry median Piotroski F-Score is 5.00. PT Bundamedik Tbk's value of 6 is 20% above this benchmark. Historically, PT Bundamedik Tbk's own Piotroski F-Score has ranged from 4.00 to 7.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 5.00, PT Bundamedik Tbk has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Healthcare Providers & Services company?
The median Piotroski F-Score among Healthcare Providers & Services companies is 5.00, based on 650 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Bundamedik Tbk's current Piotroski F-Score of 6 is 20% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on PT Bundamedik Tbk and its competitors. For the Healthcare Providers & Services industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Bundamedik Tbk's current Piotroski F-Score is 6, which is near median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Bundamedik Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Bundamedik Tbk (ISX:BMHS) is currently considered Possible Value Trap. The stock's GF Value™ is Rp304.24, compared to a current price of Rp179.00 — trading 41.2% below its estimated fair value. The current Piotroski F-Score is 6, which is near median its 10-year median of 6.00 and 20% above the Healthcare Providers & Services industry median of 5.00. PT Bundamedik Tbk's overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For PT Bundamedik Tbk (ISX:BMHS), the current Piotroski F-Score is 6 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Bundamedik Tbk (ISX:BMHS) Overvalued in 2026?
Based on GuruFocus' analysis, PT Bundamedik Tbk stock appears to be undervalued.
The current stock price of Rp179.00 is trading 41.2% below its estimated GF Value™ of Rp304.24.
GuruFocus considers PT Bundamedik Tbk to be Possible Value Trap.
Key valuation signals for ISX:BMHS:
Piotroski F-Score: 6 (near median its 10-year median of 6.00)
GF Value™: Rp304.24 vs. price of Rp179.00 (41.2% below fair value)
Industry Position: 20% above the Healthcare Providers & Services median (#165 of 650)
No single metric tells the full story. See the ISX:BMHS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Bundamedik Tbk is a healthcare service provider. The Company carries out its main business activities through private hospital activities. It offers maternal and child health services, outpatient services, inpatient services, emergency services, service excellence centers, IVF services, and Clinical laboratory services.
61GF Score
Get the complete analysis for ISX:BMHS
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:BMHS has been successfully added to your 
